N
Nikki R. Kong
Researcher at Brigham and Women's Hospital
Publications - 19
Citations - 652
Nikki R. Kong is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Haematopoiesis & Embryonic stem cell. The author has an hindex of 11, co-authored 18 publications receiving 509 citations. Previous affiliations of Nikki R. Kong include Harvard University & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Stem Cell Factor SALL4 Represses the Transcriptions of PTEN and SALL1 through an Epigenetic Repressor Complex
Jiayun Lu,Ha-Won Jeong,Nikki R. Kong,Youyang Yang,John Carroll,Hongbo R. Luo,Leslie E. Silberstein,YupoMa,Li Chai +8 more
TL;DR: It is the first to demonstrate that stem cell protein SALL4 represses its target genes, PTEN and SALL1, through the epigenetic repressor Mi-2/NuRD complex.
Journal ArticleDOI
SALL4, the missing link between stem cells, development and cancer.
TL;DR: This review aims to summarize the current knowledge of Sall4, including a SALL4-based approach to classify and target cancers, and questions about this important gene still remain unanswered, specifically, on how this gene regulates cell fates at a molecular level.
Journal ArticleDOI
Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia
TL;DR: The similar expression pattern of SALL4 in acute myeloid leukemia and B-cell lymphoblastic leukemia/lymphomas suggests that these two disease entities may share similar biological features and/or mechanisms of leukemogenesis.
Journal ArticleDOI
SALL4 is a key transcription regulator in normal human hematopoiesis
Chong Gao,Nikki R. Kong,Ailing Li,Hiro Tatetu,Shikiko Ueno,Youyang Yang,Jie He,Jianchang Yang,Yupo Ma,Grace Kao,Daniel G. Tenen,Li Chai +11 more
TL;DR: The mechanism(s) by which SALL4 functions in normal human hematopoiesis, including identification of its target genes, still need to be explored.
Journal ArticleDOI
New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation
Justin L. Tan,Justin L. Tan,Feng Li,Joanna Z. Yeo,Joanna Z. Yeo,Kol Jia Yong,Mahmoud A. Bassal,Mahmoud A. Bassal,Guo Hao Ng,May Yin Lee,Chung Yan Leong,Hong Kee Tan,Chan Shuo Wu,Bee Hui Liu,Tim Chan,Zi Hui Tan,Yun Shen Chan,Siyu Wang,Zhi Han Lim,Tan Boon Toh,Lissa Hooi,Kia Ngee Low,Siming Ma,Nikki R. Kong,Alicia Stein,Yue Wu,Yue Wu,Matan Thangavelu Thangavelu,Atsushi Suzuki,Giridharan Periyasamy,John M. Asara,Yock Young Dan,Yock Young Dan,Glenn Kunnath Bonney,Edward Kai-Hua Chow,Guo-Dong Lu,Guo-Dong Lu,Huck-Hui Ng,Yoganathan Kanagasundaram,Siew Bee Ng,Wai Leong Tam,Daniel G. Tenen,Daniel G. Tenen,Li Chai +43 more
TL;DR: In a screen for compounds that reduce the viability of cells that express high levels of the transcription factor SALL4, inhibitors of oxidative phosphorylation were identified, which slowed the growth of xenograft tumors from Sall4hi cells in mice.